These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Synthesis, structure-activity relationship studies, and identification of novel 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 1. Sifferlen T; Koberstein R; Cottreel E; Boller A; Weller T; Gatfield J; Brisbare-Roch C; Jenck F; Boss C Bioorg Med Chem Lett; 2013 Apr; 23(7):2212-6. PubMed ID: 23434414 [TBL] [Abstract][Full Text] [Related]
26. Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonists. Pettersson H; Bülow A; Ek F; Jensen J; Ottesen LK; Fejzic A; Ma JN; Del Tredici AL; Currier EA; Gardell LR; Tabatabaei A; Craig D; McFarland K; Ott TR; Piu F; Burstein ES; Olsson R J Med Chem; 2009 Apr; 52(7):1975-82. PubMed ID: 19338356 [TBL] [Abstract][Full Text] [Related]
27. Pyrrolo[1,2-a]pyrazine and pyrazolo[1,5-a]pyrazine: novel, potent, and selective series of Vasopressin 1b receptor antagonists. Arban R; Bianchi F; Buson A; Cremonesi S; Di Fabio R; Gentile G; Micheli F; Pasquarello A; Pozzan A; Tarsi L; Terreni S; Tonelli F Bioorg Med Chem Lett; 2010 Sep; 20(17):5044-9. PubMed ID: 20674355 [TBL] [Abstract][Full Text] [Related]
28. Recent advances in the research and development of CB1 antagonists. Smith RA; Fathi Z IDrugs; 2005 Jan; 8(1):53-66. PubMed ID: 15650943 [TBL] [Abstract][Full Text] [Related]
29. The discovery of novel indole-2-carboxamides as cannabinoid CB(1) receptor antagonists. Cowley PM; Baker J; Barn DR; Buchanan KI; Carlyle I; Clark JK; Clarkson TR; Deehan M; Edwards D; Goodwin RR; Jaap D; Kiyoi Y; Mort C; Palin R; Prosser A; Walker G; Ward N; Wishart G; Young T Bioorg Med Chem Lett; 2011 Jan; 21(1):497-501. PubMed ID: 21075628 [TBL] [Abstract][Full Text] [Related]
30. Oxadiazole-diarylpyrazole 4-carboxamides as cannabinoid CB1 receptor ligands. Lee SH; Seo HJ; Kim MJ; Kang SY; Song KS; Lee SH; Jung ME; Kim J; Lee J Bioorg Med Chem Lett; 2009 Apr; 19(7):1899-902. PubMed ID: 19269817 [TBL] [Abstract][Full Text] [Related]
32. Synthesis and anti-mycobacterial evaluation of some pyrazine-2-carboxylic acid hydrazide derivatives. Abdel-Aziz M; Abdel-Rahman HM Eur J Med Chem; 2010 Aug; 45(8):3384-8. PubMed ID: 20488590 [TBL] [Abstract][Full Text] [Related]
33. Identification and hit-to-lead optimization of a novel class of CB1 antagonists. Letourneau JJ; Jokiel P; Olson J; Riviello CM; Ho KK; McAleer L; Yang J; Swanson RN; Baker J; Cowley P; Edwards D; Ward N; Ohlmeyer MH; Webb ML Bioorg Med Chem Lett; 2010 Sep; 20(18):5449-53. PubMed ID: 20719511 [TBL] [Abstract][Full Text] [Related]
34. Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results. Fernández-Fernández C; Callado LF; Girón R; Sánchez E; Erdozain AM; López-Moreno JA; Morales P; Rodríguez de Fonseca F; Fernández-Ruiz J; Goya P; Meana JJ; Martín MI; Jagerovic N Drug Des Devel Ther; 2014; 8():263-77. PubMed ID: 24591816 [TBL] [Abstract][Full Text] [Related]
35. Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists. Hartz RA; Ahuja VT; Arvanitis AG; Rafalski M; Yue EW; Denhart DJ; Schmitz WD; Ditta JL; Deskus JA; Brenner AB; Hobbs FW; Payne J; Lelas S; Li YW; Molski TF; Mattson GK; Peng Y; Wong H; Grace JE; Lentz KA; Qian-Cutrone J; Zhuo X; Shu YZ; Lodge NJ; Zaczek R; Combs AP; Olson RE; Bronson JJ; Mattson RJ; Macor JE J Med Chem; 2009 Jul; 52(14):4173-91. PubMed ID: 19552437 [TBL] [Abstract][Full Text] [Related]
36. Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. Colotta V; Lenzi O; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Traini C; Pedata F; Morizzo E; Moro S J Med Chem; 2009 Apr; 52(8):2407-19. PubMed ID: 19301821 [TBL] [Abstract][Full Text] [Related]
37. Discovery of 2-(alpha-methylbenzylamino) pyrazines as potent Type II inhibitors of FMS. Burns CJ; Harte MF; Bu X; Fantino E; Giarrusso M; Joffe M; Kurek M; Legge FS; Razzino P; Su S; Treutlein H; Wan SS; Zeng J; Wilks AF Bioorg Med Chem Lett; 2009 Feb; 19(4):1206-9. PubMed ID: 19128971 [TBL] [Abstract][Full Text] [Related]
38. A novel series of 2-pyridyl-containing compounds as lysophosphatidic acid receptor antagonists: development of a nonhydrolyzable LPA3 receptor-selective antagonist. Heasley BH; Jarosz R; Carter KM; Van SJ; Lynch KR; Macdonald TL Bioorg Med Chem Lett; 2004 Aug; 14(15):4069-74. PubMed ID: 15225728 [TBL] [Abstract][Full Text] [Related]
39. Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity. Dow RL; Carpino PA; Hadcock JR; Black SC; Iredale PA; DaSilva-Jardine P; Schneider SR; Paight ES; Griffith DA; Scott DO; O'Connor RE; Nduaka CI J Med Chem; 2009 May; 52(9):2652-5. PubMed ID: 19351113 [TBL] [Abstract][Full Text] [Related]
40. Discovery of cannabinoid-1 receptor antagonists by virtual screening. Lee GN; Kim KR; Ahn SH; Bae MA; Kang NS Bioorg Med Chem Lett; 2010 Sep; 20(17):5130-2. PubMed ID: 20667724 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]